eb103
eb103: sourced relationships with 1 company · 1 clinical trial tracked.
eb103 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect eb103 to ESLA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could eb103 → ESLA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Estrella Immunopharma Inc. (ESLA) B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Primary endpoint: To assess the safety and tolerability of EB103.
Interventionalopen27 targetStarted 2024-06Completion 2028-075 sites · United StatesEstrella Immunopharma, Inc.
Frequently asked questions
Which companies have sourced relationships with eb103?
eb103 has dated SEC/FDA relationship records for Estrella Immunopharma Inc..
How many clinical trials involve eb103?
BioSniper tracks 1 clinical trial involving eb103.